Opportunities this week:

Despite the recent downward correction seen in GSK’s shares, we view it as a fundamentally solid healthcare business with a strong franchise, as such, we reiterate our BUY rating on the stock. (BUY PT: 1890p)
Given the selloff in Kingspan’s shares over the last month (-10% in June) and the possibility the company’s H1 guidance may prove overly conservative, we believe it is an opportune time to highlight the stock as a buying opportunity. (BUY PT: €94.10)
In our view, the recent pullback in Glanbia’s shares appears unwarranted, providing an attractive entry point for investors. (BUY PT €21.50)